InvestSMART

Cambium Bio Limited (ASX: CMB) - Announcements

Current share price for CMB : $0.400 0.04 (11.11%)+

ASX company news and announcements for Cambium Bio Limited (CMB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cambium Bio Limited (CMB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cambium Bio Limited (CMB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cambium Bio Limited (CMB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$12 Updated Securities Trading Policy 5 Aug 2026 9:31AM $0.410 $0.400 fallen by 2.44%
$12 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2026 8:51AM $0.430 $0.400 fallen by 6.98%
$12 Change in substantial holding - BW 24 Jul 2026 9:37AM $0.430 $0.400 fallen by 6.98%
$12 Cleansing Notice 24 Jul 2026 9:07AM $0.430 $0.400 fallen by 6.98%
$12 Application for quotation of securities - CMB 24 Jul 2026 9:04AM $0.430 $0.400 fallen by 6.98%
$12 Proposed issue of securities - CMB 22 Jul 2026 8:46AM $0.410 $0.400 fallen by 2.44%
$12 Cambium Bio Raises A$1.0 Million via Placement 22 Jul 2026 8:44AM $0.410 $0.400 fallen by 2.44%
$12 Becoming a substantial holder 24 Jun 2026 12:12PM $0.460 $0.400 fallen by 13.04%
$12 Change in substantial holding - ZYBT 24 Jun 2026 10:28AM $0.460 $0.400 fallen by 13.04%
$12 Becoming a substantial holder 16 Jun 2026 10:43AM $0.435 $0.400 fallen by 8.05%
$12 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:10AM $0.450 $0.400 fallen by 11.11%
$12 FDA Confirms Single Pivotal Trial Pathway for Elate Ocular 23 Apr 2026 1:01PM $0.385 $0.400 risen by 3.90%
$12 Change of Directors Interest Notice - ST 24 Mar 2026 4:31PM $0.480 $0.400 fallen by 16.67%
$12 Cleansing Notice 17 Mar 2026 9:38AM $0.480 $0.400 fallen by 16.67%
$12 Application for quotation of securities - CMB 17 Mar 2026 9:21AM $0.480 $0.400 fallen by 16.67%
$12 Results of General Meeting 16 Mar 2026 1:23PM $0.480 $0.400 fallen by 16.67%
$12 Half Year Report and Accounts 20 Feb 2026 9:39AM $0.525 $0.400 fallen by 23.81%
$12 Proposed issue of securities - CMB 11 Feb 2026 10:52AM $0.570 $0.400 fallen by 29.82%
$12 Notice of General Meeting/Proxy Form 11 Feb 2026 10:52AM $0.570 $0.400 fallen by 29.82%
$12 Quarterly Activities/Appendix 4C Cash Flow Report 23 Jan 2026 9:14AM $0.550 $0.400 fallen by 27.27%
$12 Proposed issue of securities - CMB 20 Jan 2026 8:19AM $0.460 $0.400 fallen by 13.04%
$12 Cambium Bio Secures A$2.4 Million Strategic Investment 20 Jan 2026 8:19AM $0.460 $0.400 fallen by 13.04%
$12 Quarterly Activities/Appendix 4C Cash Flow Report 27 Oct 2025 3:50PM $0.485 $0.400 fallen by 17.53%
$12 Corrective Appendix 3Y Terrence Walts 27 Oct 2025 3:20PM $0.485 $0.400 fallen by 17.53%
$12 Change of Directors Interest Notice - TW 24 Oct 2025 8:18AM $0.480 $0.400 fallen by 16.67%

1 - 25 of 128 results

Page 1 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.